-- Urovant became a wholly owned subsidiary of Sumitovant and announced the continuation of its Phase 2a study with novel gene therapy, URO-902 in OAB and urinary incontinence --
-- Myovant, a publicly listed company that is majority owned by Sumitovant, made key executive appointments and announced product and pipeline accomplishments including the commercial availability of its first FDA approved product, ORGOVYXâ„¢ (relugolix) for advanced prostate cancer, and positive Phase 3 trial results for relugolix in uterine fibroids and endometriosis --
PR Newswire
LONDON and NEW YORK, May 26, 2021
